- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Apr 1, 2022
Distillery Therapeutics
Small molecule ghrelin receptor agonist for hyperdopaminergia
BioCentury | Feb 11, 2022
Distillery Therapeutics
Simultaneously inhibiting ASM and activating GHSR for Alzheimer’s
BioCentury | Aug 22, 2019
Distillery Therapeutics
Enhancing dopamine receptor and ghrelin receptor activity to prevent β amyloid damage
BioCentury | Dec 14, 2017
Translation in Brief
Ghrelin’s LEAP forward
How LEAP2 could become a new target for metabolic diseases
BioCentury | Aug 4, 2017
Clinical News
FDA accepts Aeterna's resubmitted NDA for GHD candidate Macrilen
Items per page:
1 - 10 of 81